SCHEMBL4299757

SCHEMBL4299757

O=C1C(O)=C(c2ccccc2)C(c2ccc(CO)o2)N1CCCn1ccnc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.51
ANXA2 P07355 1/20 0.49
S100A10 P60903 1/20 0.49
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 10/20 0.44
MDM2 Q00987 10/20 0.44
TSHR P16473 1/20 0.44
PPARG P37231 1/20 0.42
NCOR2 Q9Y618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4300458 0.93 KDM4E (0.47) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4290800 0.91 RXFP1 (0.44) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4295524 0.89 KDM4E (0.53) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4293708 0.85 QPCT (0.44) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4305549 0.85 KDM4E (0.55) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4291443 0.84 RXFP1 (0.62) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4305591 0.84 KDM4E (0.52) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4298543 0.83 RXFP1 (0.63) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4296872 0.82 KDM4E (0.50) RXFP1ANXA2S100A10KDM4EMEN1
SCHEMBL4303721 0.81 ANXA2 (0.61) RXFP1ANXA2S100A10KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US claimed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US claimed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-8278345-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2012-10-02 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-10-29 US disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269301-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL RXFP1 1183/4885ANXA2 4727/4885S100A10 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.